PRODUCT TYPES – Page 23

Biologic freeze-thaw cycle deviation during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms or signals indicative of a deviation is the first step in any investigation. Common symptoms that may signal a freeze-thaw cycle deviation include:Click to read the full article.

Stability degradation after cleaning cycle change: CAPA aligned to regulatory expectations

Detecting stability degradation begins with observing signals within the manufacturing and quality control environments. These symptoms may not always be straightforward, but several key indicators can alert personnel to potential…

Biologic glycosylation shift (CQAs) outside trend after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Identifying symptoms indicative of a potential glycosylation shift is critical for initiating a timely investigation. Some common signals include:Click to read the full article.

Cleaning validation failure during inspection readiness: GMP investigation and containment strategy

A cleaning validation failure may manifest through various symptoms or signals that can occur either on the production floor or during laboratory testing. Identifying these symptoms promptly is critical for…

Biologic viral clearance validation gap during PPQ / process validation: how to document root cause when multiple unit operations are involved

The first step in identifying a biologic viral clearance validation gap involves recognizing relevant symptoms or signals that indicate potential deviations in the manufacturing process. Common symptoms to monitor include:Click…

Cleaning validation failure during multi-product campaign: facility and HVAC risk mitigation

Identifying symptoms or signals indicative of cleaning validation failure is the first step in addressing potential issues. These symptoms can arise from various sources within the manufacturing process, including equipment…

Biologic host cell protein (HCP) OOS during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms and signals that indicate potential HCP OOS results is the first step in effectively managing the issue. Common signs include:Click to read the full article.

Potency variability during CPV review: facility and HVAC risk mitigation

Identifying potency variability requires acute awareness of symptoms and signals during both the manufacturing process and laboratory analysis. Common indicators include:Click to read the full article.

Biologic cold chain excursion impact during deviation investigation board review: investigation strategy aligned to FDA/EMA expectations and comparability principles

Cold chain excursions can manifest as various symptoms within the manufacturing and quality control environments. Identifying these symptoms promptly is crucial for initiating an effective investigation. Here are some common…

Stability degradation during CPV review: GMP investigation and containment strategy

The initial step in managing stability degradation is recognizing the symptoms or signals that indicate a problem. In a manufacturing or quality control laboratory setting, these may include:Click to read…

Biologic host cell protein (HCP) OOS after upstream media/raw material change: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms or signals indicating potential issues in upstream processing is critical for timely intervention. Common signals that may indicate a problem with HCPs include:Click to read the full article.

Blend uniformity OOS during multi-product campaign: GMP investigation and containment strategy

Identifying symptoms related to blend uniformity is crucial for timely intervention. The following signals may suggest that an OOS situation has occurred:Click to read the full article.